REHOVOT, Israel, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading biotechnology
company for the improvement of crop productivity, announced today that it will release its financial results for the third quarter
of 2016 on Monday, November 21, 2016.
On the day of the announcement, the Company’s management will host a conference call to discuss the results at
09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-668-9141 toll free from the United
States, or +972-3-918-0610 internationally. Access to the call will also be available via live webcast through the Company’s
website at www.evogene.com.
A replay of the conference call will be available approximately three hours following the completion of the
call. To access the replay, please dial 1-888-254-7270 toll free from the United States, or +972-3-925-5937 internationally. The
replay will be accessible through November 23, 2016, and an archive of the webcast will be available on the Company’s website
through December 2, 2016.
About Evogene Ltd.:
Evogene (NYSE:EVGN) (TASE:EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and
fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to
diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control); and
ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit
www.evogene.com or contact the Company at info@evogene.com.
This press release contains "forward-looking statements" relating to future
events. These statements may be identified by words such as "may", "could",
“expects”, "intends", “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar
meaning. Such statements are based on current expectations, estimates, projections and assumptions,
describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and
are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ
materially from what is expressed or implied by such forward-looking statements due to a variety of
factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in
Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to
update these forward-looking statements to reflect future events or developments or changes in expectations, estimates,
projections and assumptions.
Contact: Karen Mazor, Director Investor Relations E: IR@evogene.com T: +972 54 228 2039
